Experimental: Dupilumab

Phase 2Monoclonal antibody

TTechnical University of Munich

Experimental: Dupilumab is one of 2 small molecule programs targeting Nummular Eczema. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nummular EczemaActive, not recruiting

Nummular EczemaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Nummular Eczema

#DrugCompanyPhaseTrials

EBGLYSS

Eli Lilly

Phase 3

1 2

Experimental: Dupilumab

TTechnical University of Munich

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Nummular Eczema

NCT04600362

Clinical

Trials by Indication[1]

Nummular Eczema1 trial

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

Active, not recruiting·TTechnical University of Munich·Phase 2·NCT04600362·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Experimental: Dupilumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Experimental: Dupilumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Experimental: Dupilumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Technical University of Munich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TTechnical University of Munich

Experimental: Dupilumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Nummular Eczema1 trial

References

Drug Info

Quick Facts

Related News